Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding in Legend By Molly Wen
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your portfolio?
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy compared to standard treatments. Safety data align with the approved label.
